ARKG Holdings of Adaptive Biotechnologies (ADPT) - Updated Daily
Join Premium Plan
Key Statistics
Statistics
Clinical Trials (6)
Institutional Ownership Trends
News That Matters
| 🕵🏼Found In | 🏷Last Price |
|---|---|
| ARKG | $13.22 |
| ⚖️Weighting | 🧢Market Cap |
| 2.74% | $1.87b |
| 🏋🏿♂️Weight Rank In ARKG | 🧮Price to Sales |
| 13 | 12.13 |
| 🏋️♀️Weight Rank Across All Funds | 🌏Country |
| 40 | 🇺🇸United States |
| 💳ARK Estimated Cost Average | 🎫ARK Ownership Percent |
| 5.33% |
| Description | |
|---|---|
| Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Its proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have three commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. | |
| Website | |
| www.adaptivebiotech.com |
Research Notes and Commentary for ADPT
March 22, 2020